Jiangsu Run'an Pharmaceutical Co, Ltd., subsidiaria omnino possessa de Jiangsu Chiatai Qingjiang Pharmaceutical Co, Ltd., modernus summus tech pharmaceuticus societas specialis in R&D, productionis et venditio fertilitatis ordinandae medicinae et varietatis APIs. Project constructionem mense Novembri 2018 incepit, LIX mu aream obtegens, cum tota obsidione 160 decies Yuan et tota area aedificium 25000 quadratum metrorum.
Praecipua activum medicamentum pharmaceuticum (API) producta: Hydrochloridem Gemcitabinum, Celecoxib, Bromhexinum HCl, Iguratimod, Apremilast, Citrate Tofactinib, Crisaborole, Urapidil Hydrochloride, Sugammadex Natri, Garlicin, Dexmedetomidine Hydrochloridis, Rocuronium Bromidum, Finerenone, etc. elit mundi genus facti et productorum gignentium opificem per constantem emendationem et innovationem in technologiarum, et occasiones praeclarum negotium praebent sodalibus nostris per orbem terrarum. Munus nostrum ad praestantes operas emptores nobis permisit solidas relationes cum sociis nostris toto orbe includere.
Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N- (2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus productum nomen: Bromhexine Hydrochloride API
Cas#611-75-6
Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N- (2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus operis nomen: Bromhexine HCl API
Cas#611-75-6